Annexon, Inc. (ANNX)
| Market Cap | 757.33M +113.1% |
| Revenue (ttm) | n/a |
| Net Income | -198.96M |
| EPS | -1.03 |
| Shares Out | 190.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,465,607 |
| Open | 4.140 |
| Previous Close | 4.190 |
| Day's Range | 3.870 - 4.180 |
| 52-Week Range | 2.540 - 7.180 |
| Beta | 1.44 |
| Analysts | Buy |
| Price Target | 17.00 (+328.21%) |
| Earnings Date | Nov 9, 2026 |
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ANNX stock is "Buy." The 12-month stock price target is $17.0, which is an increase of 328.21% from the latest price.
News
Annexon reports Q3 EPS (25c), consensus (28c)
Cash, cash equivalents and short-term investments were $213.4M as of September 30, which are expected to fund operations and anticipated milestones into 2028. “Annexon (ANNX) is well-positioned for a ...
Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Pack...
Annexon Earnings release: Q3 2026
Annexon released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Annexon Quarterly report: Q3 2026
Annexon has published its Q3 2026 quarterly earnings report on November 9, 2026.
Annexon Transcript: Study update
ARCHER II targets vision-loss protection, with its month 15 readout expected in Q4 2026.
Annexon Slides: Study update
Annexon has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat...
Annexon price target raised to $25 from $14 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Annexon (ANNX) to $25 from $14 and keeps a Buy rating on the shares. The firm cites increased confidence in the company’s…
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat...
Annexon Slides: Investor presentation
Annexon has posted slides in relation to its latest quarterly earnings report, which was published on October 2, 2026.
Annexon price target raised to $15 from $14 at JPMorgan
JPMorgan raised the firm’s price target on Annexon (ANNX) to $15 from $14 and keeps an Overweight rating on the shares. Topline 15-month data from the Phase 3 ARCHER II…
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Tri...
Annexon Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted late-stage programs in geographic atrophy and Guillain-Barré syndrome, with phase III data showing strong vision preservation and rapid patient recovery, respectively. The GA program’s dual primary endpoints and robust design position it for global regulatory filings and significant market impact.
Annexon Transcript: Wells Fargo 21st Annual Healthcare Conference
Late-stage programs in GBS and GA are advancing, with strong clinical data and regulatory filings in progress. The GA study's unique focus on functional vision and mechanistic differentiation positions it for significant market impact, while the GBS program shows rapid, meaningful patient benefit and a targeted commercial approach.
Annexon to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflamma...
Annexon price target raised to $14 from $10 at JPMorgan
JPMorgan raised the firm’s price target on Annexon (ANNX) to $14 from $10 and keeps an Overweight rating on the shares after having hosted a call focused on tanruprubart in…
Annexon participates in a conference call with JPMorgan
Conference call with management will be held on August 17 at 12 pm hosted by JPMorgan.Webcast Link
Annexon reports Q2 EPS (28c), consensus (24c)
Cash, cash equivalents and short-term investments were $209.2M as of June 30, 2026. Annexon’s (ANNX) current cash, cash equivalents and short-term investments and funds from the credit facility are ex...
Annexon expands Phase 3 ARCHER II trial
Annexon (ANNX) announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of…
Annexon upgraded to Market Perform from Underperform at Citizens
Citizens analyst Jonathan Wolleben upgraded Annexon (ANNX) to Market Perform from Underperform without a price target The firm says adding vision preservation at month 24 as an independent, dual prima...
Annexon Earnings Call Transcript: Q2 2026
Expanded phase III trial for GA with a new 24-month endpoint and reported rapid, positive results for GBS therapy. Financial position strengthened with a $200M credit facility, and key regulatory filings are on track for both programs.
Annexon Earnings release: Q2 2026
Annexon released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Annexon Quarterly report: Q2 2026
Annexon has published its Q2 2026 quarterly earnings report on August 12, 2026.
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submissio...
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinfla...